Answers are grounded in this paper and cite their sources.
OBJECTIVE: Ferumoxytol is increasingly reported as an alternative to gadolinium-based contrast agents for MR angiography (MRA), particularly for patients with renal failure. This article summarizes more than 3 years of clinical experience with ferumoxytol-enhanced MRA for a range of indications and anatomic regions. CONCLUSION: Ferumoxytol-enhanced MRA has many advantages including that it is safe for patients with renal failure and provides a lengthy plateau of vascular signal as a blood pool agent that allows longer navigated MRA sequences.
No takes yet. Share an insight, caveat, or question.
Hope et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: